Skip to main content
Clinical Trials/NCT07377695
NCT07377695
Recruiting
Not Applicable

Comparison of Remimazolam Consumption According to Administration Method in Patients Undergoing Cerebrovascular Bypass Surgery: A Prospective Randomized Trial

Seoul National University Hospital2 sites in 1 country58 target enrollmentStarted: February 4, 2026Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
58
Locations
2
Primary Endpoint
Total Consumption of Remimazolam

Overview

Brief Summary

The purpose of this prospective randomized controlled trial is to compare the total consumption of remimazolam between two different administration methods-Target-Controlled Infusion (TCI) and manual infusion-in patients undergoing cerebrovascular bypass surgery.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Health Services Research
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
19 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients scheduled to undergo cerebrovascular bypass surgery under general anesthesia.
  • American Society of Anesthesiologists (ASA) Physical Status 1, 2, or 3
  • Adults aged 19 years or older
  • Patients who have provided prior written informed consent to participate in the study

Exclusion Criteria

  • Patients who do not consent to participate in the research
  • Patients classified as ASA Physical Status 4
  • Patients with a BMI ≤18.5 kg/m2 or 35.0 ≥ kg/m2
  • History of allergy to benzodiazepine-class medications
  • Patients with acute narrow-angle glaucoma
  • Patients in a state of shock or coma
  • Acute alcohol intoxication with suppressed vital signs , or patients with alcohol or drug dependency
  • Presence of Sleep Apnea Syndrome or severe/acute respiratory failure
  • Patients with lactose intolerance or hypersensitivity to Dextran 40

Arms & Interventions

TCI

Experimental

Remimazolam administered via TCI (target Ce 0.7 μg/mL)

Intervention: Target-Controlled Infusion (TCI) of Remimazolam (Other)

Manual Infusion

Active Comparator

Remimazolam administered via manual infusion (6 mg/kg/hr for induction, 1-2 mg/kg/hr for maintenance)

Intervention: Manual Infusion of Remimazolam (Other)

Outcomes

Primary Outcomes

Total Consumption of Remimazolam

Time Frame: From the start of anesthesia induction to the end of surgery (intraoperative period).

The total cumulative dose of remimazolam ($mg$) administered from the initiation of anesthesia induction until the completion of the surgical procedure.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Chang-Hoon Koo

Associate professor

Seoul National University Hospital

Study Sites (2)

Loading locations...

Similar Trials